Group One Trading
SPRY icon

Group One Trading’s ARS Pharmaceuticals SPRY Stock Holding History

Group One Trading’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.9K Sell
2,600
-15,400
-86% -$148K ﹤0.01% 5939
2025
Q4 		$210K Buy
18,000
+4,000
+29% +$38.9K ﹤0.01% 4329
2025
Q3 		$141K Sell
14,000
-11,400
-45% -$164K ﹤0.01% 5017
2025
Q2 		$443K Sell
25,400
-53,600
-68% -$773K ﹤0.01% 3543
2025
Q1 		$994K Buy
79,000
+57,000
+259% +$686K ﹤0.01% 2469
2024
Q4 		$232K Sell
22,000
-54,000
-71% -$756K ﹤0.01% 3818
2024
Q3 		$1.1M Sell
76,000
-574,300
-88% -$6.83M ﹤0.01% 2214
2024
Q2 		$5.53M Buy
650,300
+538,400
+481% +$4.78M 0.02% 746
2024
Q1 		$1.14M Buy
111,900
+95,700
+591% +$714K ﹤0.01% 1968
2023
Q4 		$88.8K Sell
16,200
-122,200
-88% -$535K ﹤0.01% 4566
2023
Q3 		$523K Sell
138,400
-260,100
-65% -$1.71M ﹤0.01% 2859
2023
Q2 		$2.67M Sell
398,500
-98,300
-20% -$656K 0.01% 1438
2023
Q1 		$3.23M Buy
496,800
+60,600
+14% +$466K 0.01% 1141
2022
Q4 		$3.72M Buy
436,200
+161,700
+59% +$1.05M 0.01% 1346
2022
Q3 		$1.45M Buy
274,500
+62,400
+29% +$307K ﹤0.01% 2192
2022
Q2 		$899K Buy
+212,100
New +$740K ﹤0.01% 2860

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Group One Trading's SPRY Position: Q1 2026 in Review

Group One Trading increased its ARS Pharmaceuticals (SPRY) stake by 25% in Q1 2026, buying an estimated $22.7K and bringing the position to 11,887 shares worth $95.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4778.

Group One Trading first reported a position in SPRY in Q1 2022 and has held it in 8 quarters since. The position peaked at $732K in Q3 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Group One Trading held 11,887 shares of ARS Pharmaceuticals worth $95.5K as of Q1 2026.
  • Group One Trading bought 2,370 ARS Pharmaceuticals shares in Q1 2026, an estimated $22.7K.
  • ARS Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4778 holding.
  • Group One Trading first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
  • Group One Trading's ARS Pharmaceuticals position peaked at $732K in Q3 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.